--- title: "Novavax (NVAX) news: convertible notes" url: "https://aibio.space/companies/novavax/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NVAX convertible notes news: Novavax agrees to issue $225.0 million of 4.625% convertible senior notes due 2031. Novavax, Inc. (NASDAQ: NVAX), United States." --- NVAX Novavax, Inc. NASDAQ · United States # Novavax (NVAX) news NVAX convertible notes news Debt Financing · 2025-08-21 ## [Novavax agrees to issue $225.0 million of 4.625% convertible senior notes due 2031](https://aibio.space/news/novavax-agrees-issue-225-0-million-4-625-percent-convertible-senior/) About $49.7 million of the new convertible notes would be sold for cash, and about $175.3 million would be exchanged for 2027 notes. The exchange gives Novavax no cash. The company expects to close on or about August 27, 2025. ## Latest Novavax news We have not published a story on Novavax yet. When there is news, it will appear here. ## Novavax at a glance - **Ticker**: NVAX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $719.3 million ### Related companies - [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY - [BANGI INC](https://aibio.space/companies/bangi/) OTC: BNGI - [Mineralys Therapeutics](https://aibio.space/companies/mineralys-therapeutics/) NASDAQ: MLYS - [U.S. Stem Cell](https://aibio.space/companies/u-s-stem-cell/) OTC: USRM - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) NASDAQ: TRVI - [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) NASDAQ: JSPR - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) NASDAQ: SABS - [Cartesian Therapeutics](https://aibio.space/companies/cartesian-therapeutics/) NASDAQ: RNAC ### Also on NASDAQ - [Zhengye Biotechnology Holding](https://aibio.space/companies/zhengye-biotechnology/) ZYBT - [GRI Bio](https://aibio.space/companies/gri-bio/) GRI - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) SABS - [BioNexus Gene Lab](https://aibio.space/companies/bionexus-gene-lab/) BGLC - [Cuprina Holdings (Cayman)](https://aibio.space/companies/cuprina-cayman/) CUPR - [Revelation Biosciences](https://aibio.space/companies/revelation-biosciences/) REVB ## What Novavax does Novavax is a vaccine company whose technology platform combines its Matrix-M adjuvant with protein-based recombinant nanoparticle technology. The company says Matrix-M can induce a stronger and longer-lasting immune response when added to vaccines, and it provides the adjuvant for use in partner collaborations. Its authorized COVID-19 vaccine, Nuvaxovid, uses this platform. The R21/Matrix-M adjuvant malaria vaccine was developed by the Jenner Institute, University of Oxford, is manufactured by Serum Institute of India, and is authorized in several countries. Novavax's strategy is to maximize the impact of its technology by forging partnerships for its Matrix-M adjuvant and research and development assets while keeping a lean and focused operating model. The text says Matrix-M is used in various preclinical and clinical stage programs, including a pre-clinical collaboration in oncology. Novavax was incorporated in 1987 under Delaware law, and its common stock trades on the Nasdaq Global Select Market under the symbol NVAX. | Product or program | What it is | Stage | |---|---|---| | Nuvaxovid | COVID-19 vaccine built on the Novavax technology platform | authorized | | R21/Matrix-M™ adjuvant malaria vaccine | Malaria vaccine developed by Jenner Institute, manufactured by Serum Institute of India | authorized in several countries | | Matrix-M | Adjuvant provided for vaccine collaborations and partner programs | | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/nvax-20251231.htm). ## Novavax annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.12 billion](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | [$682.2 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | | Research and development | [$342.3 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | [$391.2 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | | Net income (loss) | [$440.3 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | [-$187.5 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | | Cash from operations | [-$244.6 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | [-$87.3 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | | Cash and equivalents | [$240.6 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000018/) | [$530.2 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | | Short-term investments | [$494.4 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000018/) | [$392.9 million](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $191.5 million, plus short-term investments of $527.9 million, $719.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Novavax Has Novavax sold convertible notes? Our latest story on this, dated Aug 21, 2025: "Novavax agrees to issue $225.0 million of 4.625% convertible senior notes due 2031". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/novavax-agrees-issue-225-0-million-4-625-percent-convertible-senior/). What is the ticker symbol of Novavax? Novavax, Inc. trades under the ticker NVAX on NASDAQ. Where is Novavax listed? Novavax, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:NVAX; BMV:NVAX; BSESOF:NVV1; BX:NVV1; DUS:NVV1; FWB:NVV1; GETTEX:NVV1; HAM:NVV1; HAN:NVV1; LS:A2PKMZ; LSIN:0A3S; LSX:A2PKMZ; MUN:NVV1; SWB:NVV1; TRADEGATE:NVV1; VIE:NVAX; XETR:NVV1. What is the SEC CIK of Novavax? The SEC Central Index Key (CIK) for Novavax, Inc. is 1000694. Its filings are on SEC EDGAR. How many shares does Novavax have outstanding? 164,945,726 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Novavax listed under? Our directory records Novavax, Inc. under United States. What does Novavax do? Our directory classifies Novavax, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Novavax? The ISIN recorded for Novavax, Inc. is US6700024010. Does aibio.space cover Novavax? aibio.space lists Novavax, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Novavax incorporated? SEC records list its state or country of incorporation as DE. What does Novavax develop? Novavax is a vaccine company whose technology platform combines its Matrix-M adjuvant with protein-based recombinant nanoparticle technology. The company says Matrix-M can induce a stronger and longer-lasting immune response when added to vaccines, and it provides the adjuvant for use in partner collaborations. What is Nuvaxovid from Novavax? Nuvaxovid: COVID-19 vaccine built on the Novavax technology platform Stage: authorized. What is R21/Matrix-M™ adjuvant malaria vaccine from Novavax? R21/Matrix-M™ adjuvant malaria vaccine: Malaria vaccine developed by Jenner Institute, manufactured by Serum Institute of India Stage: authorized in several countries. What was Novavax's revenue last year? $1.12 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Novavax profitable? Novavax, Inc. reported net income of $440.3 million for the fiscal year ended Dec 31, 2025, and used $244.6 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Novavax Members talk about Novavax (NVAX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Novavax, newest first. Each line links the filing it comes from. 1. 2025-10-22 Distress Reported a material impairment charge. SEC Form 8-K (Items 1.01,2.06,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/tm2529188d1_8k.htm) 2. 2025-08-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1000694/000110465925081160/tm2524045d1_ex99-1.htm) 3. 2025-03-11 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1000694/000110465925022435/tm258808d2_8k.htm) 4. 2024-12-30 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01). [Source](https://www.sec.gov/Archives/edgar/data/1000694/000110465924132569/tm2432218d1_8k.htm) 5. 2024-11-05 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). [Source](https://www.sec.gov/Archives/edgar/data/1000694/000110465924114376/tm2427595d1_8k.htm) ## Press releases Headlines of Novavax's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-29 PR Newswire [Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe](https://www.prnewswire.com/news-releases/novavax-earns-125-million-milestone-as-sanofi-launches-phase-3-influenza-covid-19-combination-vaccine-trial-in-europe-302923786.html) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NVAX on TradingView](https://www.tradingview.com/symbols/NASDAQ-NVAX/). ## SEC filings and registration - **SEC name**: Novavax Inc - **CIK**: 1000694 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: NVAX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 21 FIRSTFIELD RD, GAITHERSBURG, MD - **Phone**: 240-268-2000 - **Shares outstanding**: 164,945,726 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/nvax-20260806.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000018/nvax-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1000694/000110465926076648/tm2618472d1_8k.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/nvax-20260506.htm) filed 2026-05-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000162828026030917/nvax-20260331.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1000694/000162828026027328/nvax-20260427.htm) filed 2026-04-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000011/nvax-20260226.htm) filed 2026-02-26 - [10-K](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/nvax-20251231.htm) filed 2026-02-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001000694), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Novavax, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NVAX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Novavax, Inc. - **Ticker**: NVAX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US6700024010 - **Other listed symbols**: BIVA:NVAX; BMV:NVAX; BSESOF:NVV1; BX:NVV1; DUS:NVV1; FWB:NVV1; GETTEX:NVV1; HAM:NVV1; HAN:NVV1; LS:A2PKMZ; LSIN:0A3S; LSX:A2PKMZ; MUN:NVV1; SWB:NVV1; TRADEGATE:NVV1; VIE:NVAX; XETR:NVV1 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NVAX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/novavax/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Novavax (NVAX) news: convertible notes", 2026-10-31, https://aibio.space/companies/novavax/